info@allievapharma.com

  • 24/7
    Customer Service
  • ISO 9001
    Certification Company
  • WHO-GMP
    Certified Company

Gonadotropin-Releasing Hormone (GnRH) Agonist

Gonadotropin-Releasing Hormone (GnRH) Agonist Products

Discover a wide range of Gonadotropin-Releasing Hormone (GnRH) Agonist products under the Hormonal Antineoplastic category. Allieva Pharma provides high-quality pharmaceutical solutions trusted across India and global markets.

LEUPOLIEVA DEPOT 3.75 MG Leuprolide Acetate Depot for Injection 3.75 mg by LEUPOLIEVA DEPOT 3.75 MG

LEUPOLIEVA DEPOT 3.75 MG

Leuprolide Acetate Depot for Injection 3.75 mg

LEUPOLIEVA DEPOT 3.75 MG (Leuprolide Acetate Depot for Injection 3.75 mg) is a prescription hormonal medicine containing Leuprolide Acetate 3.75 mg in a long-acting depot formulation. Leuprolide belongs to the Gonadotropin-Releasing Hormone (GnRH) Agonist class and is used to suppress the production of sex hormones. When administered continuously, Leuprolide initially stimulates the pituitary gland and subsequently reduces the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in a significant reduction in testosterone production in males and estrogen production in females. LEUPOLIEVA DEPOT 3.75 MG may be used in the management of advanced prostate cancer, endometriosis, uterine fibroids, and other approved hormone-dependent conditions, depending on the patient's clinical condition and the prescribing information applicable to the product. The depot formulation is designed to provide sustained release of Leuprolide Acetate, helping maintain hormonal suppression over the prescribed treatment interval. The injection should be prepared and administered by a qualified healthcare professional. LEUPOLIEVA DEPOT 3.75 MG is commonly used for: Advanced Prostate Cancer Hormone-Dependent Prostate Cancer Endometriosis Uterine Fibroids Hormonal Suppression Therapy Androgen Deprivation Therapy Hormone-Dependent Conditions Patients receiving Leuprolide therapy require regular monitoring of treatment response and relevant clinical parameters.

View Details
LEUPOLIEVA DEPOT 11.25 MG Leuprolide Acetate Depot for Injection 11.25 mg by LEUPOLIEVA DEPOT 11.25 MG

LEUPOLIEVA DEPOT 11.25 MG

Leuprolide Acetate Depot for Injection 11.25 mg

LEUPOLIEVA DEPOT (Leuprolide Acetate Depot for Injection 11.25 mg) is a prescription hormonal medicine containing Leuprolide Acetate 11.25 mg in a long-acting depot formulation. Leuprolide is a Gonadotropin-Releasing Hormone (GnRH) agonist used in the management of hormone-dependent conditions and certain cancers. Leuprolide initially stimulates the pituitary gland to release gonadotropins. With continued administration, it suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in a significant reduction in testosterone levels in males and estrogen levels in females. LEUPOLIEVA DEPOT 11.25 MG is commonly used in the management of advanced prostate cancer and may also be prescribed for certain hormone-dependent conditions such as endometriosis and uterine fibroids, depending on the approved indication and treatment plan. The depot formulation is designed to provide sustained release of Leuprolide Acetate over an extended period, reducing the need for frequent administration. The medicine is administered by a qualified healthcare professional according to the prescribed treatment schedule. LEUPOLIEVA DEPOT is commonly used for: Advanced Prostate Cancer Hormone-Dependent Prostate Cancer Endometriosis Uterine Fibroids Hormonal Suppression Therapy Androgen Deprivation Therapy Oncology Treatment Programs Patients receiving Leuprolide therapy require regular monitoring of treatment response, hormone levels, and relevant clinical parameters.

View Details
  • 1

24/7 Clients Support

Best Price

Quality Assurance